Randomized Controlled Trial of Etodolac versus Combination of Etodolac and Eperisone in Patients of Knee Osteoarthritis

Abstract EN

Objective.

To compare the efficacy and tolerability of etodolac versus etodolac in combination with eperisone in patients of Osteoarthritis knee.

Patients and Methods.

A prospective, randomized, open label, parallel group, comparative study was conducted in 60 patients of knee OA over a period of 2 months.

Thirty patients received etodolac 600 mg once daily and 30 patients received eperisone 50 mg thrice daily in addition to etodolac 600 mg once daily for 8 weeks.

Efficacy assessment was done on the basis of improvement in mean scores of spontaneous pain on Visual analog scale (VAS), pain on movement, functional capacity, joint tenderness, swelling, erythema on Likert scale, and patient's overall arthritic condition on a five-point investigator scale at the end of study period as compared with the baseline scores.

Assessment of tolerability was done by recording the occurrence of adverse events.

Data was analyzed using Chi square test and students t-test.

Results.

All the enrolled patients completed the study and were compliant to the treatment regimens that they were allocated to.

Both the treatment groups showed a statistically significant improvement in all the efficacy parameters at the end of 8 weeks as compared to baseline (P<0.05) with no statistically significant difference between the groups.

Adverse events were few and mild in nature.

Conclusion.

Combination of etodolac and eperisone is as effective as etodolac alone in patients of OA knee.

Thus, it is concluded that additional use of muscle relaxant has no adjuvant value in patients of OA knee and is not recommended.

The study is registered with the Clinical Trial Registry of India vide registration number CTRI/2013/03/003442.